Baseline characteristics of patients initiated on TNFi agent
| All patients (n=454) | Etanercept (n=254) | Infliximab (n=138) | Adalimumab (n=62) | Overall p-value* | |
|---|---|---|---|---|---|
| Age, years, median (range) | 56 (18–85) | 55 (18–80) | 58 (25–82) | 56 (19–85) | 0.099 |
| Female, n (%) | 357 (78.6%) | 203 (79.9%) | 108 (78.2%) | 46 (74.2%) | 0.610 |
| Disease duration, years, median (range) | 6.0 (0.1–52.0) | 6.0 (0.1–50.0) | 5.0 (0.1–52.0) | 8.0 (0.6–40.0) | 0.187 |
| Antibody status, no. positive/no. tested (%) | |||||
| Positive RF ever | 362/453 (79.9%) | 197/253 (77.9%) | 118/138 (85.5%) | 47/62 (75.8%) | 0.135 |
| Positive ACPA ever | 302/391 (77.2%) | 172/221 (77.8%) | 93/115 (80.9%) | 37/55 (67.3%) | 0.134 |
| Seronegative for both RF and ACPA | 62/391 (15.9%) | 35/221 (15.8%) | 14/115 (12.2%) | 13/55 (23.6%) | 0.160 |
| Erosive disease, no. positive/no. tested (%) | 288/425 (67.8%) | 152/229 (66.4%) | 96/137 (70.1%) | 40/59 (67.8%) | 0.765 |
| Concomitant medications, n (%) | |||||
| Methotrexate† | 344 (75.8%) | 171 (67.3%) | 137 (99.3%) | 36 (58.1%) | <0.001 |
| Hydroxychloroquine | 38 (8.4%) | 24 (9.4%) | 7 (5.1%) | 7 (11.3%) | 0.129 |
| Sulfasalazine | 5 (1.1%) | 3 (1.2%) | 0 (0.0%) | 2 (3.2%) | 0.221 |
| Oral corticosteroid | 87 (19.2%) | 46 (18.1%) | 30 (21.7%) | 11 (17.7%) | 0.654 |
*Statistical analysis among three groups was by ANOVA with Bonferroni correction. χ2 testing was used for categorical data.
†Thirty patients, methotrexate-naive, were originally treated as a part of trial (etanercept, n=16; infliximab, n=14).
TNFi, tumour necrosis factor inhibitor.